These bullish firms believe that Cubicin, the sole marketed product at Cubist, remains a growth driver at Cubist with opportunities for further label expansion. Moreover, they are encouraged by Cubist’s favorable settlement with Teva regarding Cubicin. The settlement removes a major overhang for Cubist and makes Cubist an attractive acquisition target according to some firms.